Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

Image of Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population
based cohort study

THERAPEUTIC CLASS

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

Patorno E - Personal Name;

To evaluate the cardiovascular safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor for the
treatment of type 2 diabetes mellitus, in direct comparisons with DPP-4 inhibitors (DPP-4i), GLP-1 receptor agonists (GLP-1RA), or sulfonylureas, as used in routine practice.

Availability

Titan Center Location name is not set

REQJ565-02

Available

Detail Information

Series Title: -
Call Number: -
Publisher: : .,
Collation: -
Language: English
ISBN/ISSN: -
Classification: NONE
Content Type: -
Media Type: -
Carrier Type: -
Edition: -
Subject(s): Cardiovascular & Hematopoietic System
Specific Detail Info: BMJ 2018;360:k119
Statement of Responsibility: -

Other version/related

No other version available

File Attachment

Read Here

Comments

You must be logged in to post a comment